MADISON, Wis., April 9, 2018 /PRNewswire/ -- Exact Sciences
Corp. (Nasdaq: EXAS) today announced that the company plans to
release its first-quarter 2018 financial results after the close of
the U.S. financial markets on April 26,
2018. Following the release, company management will host a
webcast and conference call at 5 p.m.
EDT to discuss financial results and business progress.
First-Quarter 2018 Webcast & Conference Call
Details
Date:
|
Thursday, April 26,
2018
|
Time:
|
5 p.m. EDT, 4 p.m.
CDT
|
Webcast:
|
The live webcast can
be accessed at www.exactsciences.com
|
Telephone:
|
Domestic callers,
dial 877-201-0168
International callers, dial +1 647-788-4901
|
|
Access code for both
domestic and international callers: 8289286
|
An archive of the webcast will be available at
www.exactsciences.com. A replay of the conference call will
be available by calling 800-585-8367 domestically or 416-621-4642
internationally. The access code for the replay of the call is
8289286. The webcast, conference call and replay are open to all
interested parties.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused
on the early detection and prevention of the deadliest forms of
cancer. The company has exclusive intellectual property protecting
its non-invasive, molecular screening technology for the detection
of colorectal cancer. For more information, please visit the
company's website at www.exactsciences.com, follow Exact Sciences
on Twitter @ExactSciences or find Exact Sciences on Facebook.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that are intended to be covered by the "safe harbor" created by
those sections. Forward-looking statements, which are based on
certain assumptions and describe our future plans, strategies and
expectations, can generally be identified by the use of
forward-looking terms such as "believe," "expect," "may," "will,"
"should," "would," "could," "seek," "intend," "plan," "goal,"
"project," "estimate," "anticipate" or other comparable terms. All
statements other than statements of historical facts included in
this news release regarding our strategies, prospects, financial
condition, operations, costs, plans and objectives are
forward-looking statements. Examples of forward-looking statements
include, among others, statements we make regarding expected future
operating results, anticipated results of our sales and marketing
efforts, expectations concerning payer reimbursement and the
anticipated results of our product development efforts.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and financial
condition may differ materially from those indicated in the
forward-looking statements. Therefore, you should not rely on any
of these forward-looking statements. Important factors that could
cause our actual results and financial condition to differ
materially from those indicated in the forward-looking statements
include, among others, the following: our ability to successfully
and profitably market our products and services; the acceptance of
our products and services by patients and healthcare providers; our
ability to meet demand for our products and services; the
willingness of health insurance companies and other payers to cover
Cologuard and adequately reimburse us for our performance of the
Cologuard test; the amount and nature of competition from other
cancer screening and diagnostic products and services; the effects
of the adoption, modification or repeal of any healthcare reform
law, rule, order, interpretation or policy; the effects of changes
in pricing, coverage and reimbursement for our products and
services, including without limitation as a result of the
Protecting Access to Medicare Act of 2014; recommendations,
guidelines and quality metrics issued by various organizations such
as the U.S. Preventive Services Task Force, the American Cancer
Society, and the National Committee for Quality Assurance regarding
cancer screening or our products and services; our ability to
successfully develop new products and services; our success
establishing and maintaining collaborative, licensing and supplier
arrangements; our ability to maintain regulatory approvals and
comply with applicable regulations; and the other risks and
uncertainties described in the Risk Factors and in Management's
Discussion and Analysis of Financial Condition and Results of
Operations sections of our most recently filed Annual Report on
Form 10-K and our subsequently filed Quarterly Reports on Form
10-Q. We undertake no obligation to publicly update any
forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contact:
Megan
Jones
Exact Sciences Corp.
Associate Manager, Investor Relations
meganjones@exactsciences.com
608-535-8815
View original content with
multimedia:http://www.prnewswire.com/news-releases/exact-sciences-schedules-first-quarter-2018-earnings-call-300626063.html
SOURCE EXACT SCIENCES CORP